Early initiation of glecaprevir/pibrentasvir after transplantation of HCV‐viremic kidneys into HCV‐negative recipients is associated with normalization in the altered inflammatory milieu

Abstract

AbstractOur previous Multicenter Trial to Transplant HCV‐infected Kidneys (MYTHIC) observed that 100% of hepatitis C virus (HCV)‐uninfected patients who received a kidney from an HCV‐infected deceased donor were cured of HCV with an 8‐week regimen of glecaprevir and pibrentasvir (G/P) initiated 2–5 days after transplantation. Following acute and chronic infection with HCV, immune system perturbations have been reported to persist even after viral clearance. The aim of this study was to determine whether HCV viremic kidney recipients in the MYTHIC study experience sustained changes in the soluble inflammatory milieu associated with HCV infection. Among nine patients with HCV viremia at day 3 post‐kidney transplant (post‐KT D3), IP‐10, IL‐10, MIP‐1β, and IL‐8 were significantly elevated from baseline. However, over the subsequent visits, there was a rapid, dramatic reduction back to baseline levels. Among seven patients who were not HCV viremic at post‐KT D3, the cytokine levels did not significantly change. HCV‐uninfected patients who received a kidney from an HCV‐viremic deceased donor and were treated with early G/P experienced only transient alterations in the soluble inflammatory milieu. These data provide reassuring evidence that there appear to be no persistent cytokine disturbances with transient HCV viremia accompanying HCV donor positive/recipient negative kidney transplant.